ADVENTRX to Present at the BIO InvestorForum 2005 on October 19
October 13 2005 - 10:30AM
Business Wire
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that Evan
M. Levine, president and CEO, will present at the BIO InvestorForum
2005 on Wednesday, October 19 at 2:00 p.m. Pacific Time, in San
Francisco at the Palace Hotel. A link to the live audio webcast
presentation will be available via the "Investors" section of the
Company's Web site at http://www.adventrx.com/investors/events.htm.
This presentation will be available on the ADVENTRX Web site for 14
days. Attendees will include institutional investors, venture and
private equity investors, as well as research analysts and bankers
representing leading banks in the sector. Additional conference
details and online registration are available at www.bio.org. About
ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical research
and development company focused on introducing new technologies for
anticancer and antiviral treatments that improve the performance
and safety of existing drugs, by addressing significant problems
such as drug metabolism, toxicity, bioavailability and resistance.
The Company's lead compound, CoFactor(TM), is a biomodulator of
5-fluorouracil (5-FU), a widely used cancer chemotherapy. CoFactor
is currently being tested with 5-FU in a US-based Phase II and an
EU-based Phase IIb clinical trial as a first line treatment of
metastatic colorectal cancer. In addition, CoFactor has received
clearance under a special protocol assessment from the FDA to begin
a Phase III pivotal clinical trial for metastatic colorectal
cancer. More information can be found on the Company's Web site at
www.adventrx.com. Forward Looking Statements Regarding ADVENTRX
This press release contains forward-looking statements, within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, regarding ADVENTRX. Such statements
are made based on management's current expectations and beliefs.
Actual results may vary from those currently anticipated based upon
a number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last quarterly report on Form
10-Q, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof.
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024